Category Archives: Ceritinib – Zykadia from Novartis

3 Ceritinib abstracts

Abstracts 8060, 8059, and 8058 relate to Ceritinib. Please see glossary for acronym definitions. Abstract 8060 covers the Ascend 3 trial, which is a phase 2 trial that includes ALK inhibitor naive patients. As of 6-27-2014 the trial had 124 … Continue reading

Posted in Brain metastases, Ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading

Posted in 3922 by Pfizer, AP26113 - Brigatinib from Ariad, Brain metastases, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Entrectinib RXDX-101 by Ignyta, Lung cancer, Potential Treatments, Research, Side Effects, TSR-011 from Tesaro | Leave a comment

Novartis update

On May 8, 2015 Novartis announced that Zykadia (ceritinib) was approved by the European Commission to treat ALK+ lung cancer patients previously treated with Crizotinib.

Posted in Ceritinib - Zykadia from Novartis, Crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Effectivness of certain 2nd generation ALK inhibitors against specific ALK mutations

Four 2nd generation ALK inhibitors (Ceritinib, Alectinib, AP26113, and ASP3026) were tested in vitro against six known mutations of the ALK fusion gene. Generally, AP26113 was most effective and ASP3026 was least effective. In some cases one drug worked against … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Lung cancer, Research, Resistance to treatment | Leave a comment

Crizotinib followed by Ceritinib

A retrospective study of 73 patients who took Crizotinib followed by Ceritib  from 4 hospitals found positive results. The median progression free survival (PFS) on Crizotinib was 8.2 months. The median interval before starting Ceritinib was 25 days. The median … Continue reading

Posted in Ceritinib - Zykadia from Novartis, Crizotinib - Xalkori from Pfizer, Lung cancer, Research | Leave a comment

Video on Alectinib

Here is a video discussing Alectinib and comparing it with Crizotinib and Ceritinib. He also mentioned an upcoming trial that is being planned that would compare various sequences of the drugs. http://www.onclive.com/conference-coverage/thoracic-2014/Dr-Govindan-on-the-Potential-for-Alectinib

Posted in Brain metastases, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Research, Resistance to treatment | Leave a comment

Ceritinib effective on brain mets.

ALK-inhibitor naïve patients treated with ceritinib experienced an overall response rate (ORR) of 72.3% and a median progression-free survival (PFS) of 18.4 months. In ALK inhibitor treated patients, the ORR was 56.4% and the median PFS was 6.9 months. In … Continue reading

Posted in Brain metastases, Ceritinib - Zykadia from Novartis, Lung cancer, Research | Leave a comment

Video on ALK inhibitor efficacy

By Dr. Jack West http://www.onclive.com/peer-exchange/nsclc-needs/Efficacy-of-Next-Generation-ALK-Inhibitors

Posted in AP26113 - Brigatinib from Ariad, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Brain metastases, CEP-37440, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Entrectinib RXDX-101 by Ignyta, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, Side Effects, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

List of 8 ALK Inhibitors in trials

List of 8 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Pfizer – Crizotinib (2011 initial, 2013 final) Novartis – Ceritinib (2014 initial) FDA Breakthrough Status Chugai – Alectinib (approved in Japan in 2014) Ariad … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Entrectinib RXDX-101 by Ignyta, Lung cancer, Regulatory applications & approvals, Research, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment